Literature DB >> 26230354

Factors affecting the success of next-generation sequencing in cytology specimens.

Sinchita Roy-Chowdhuri1, Rashmi S Goswami2, Hui Chen1, Keyur P Patel2, Mark J Routbort2, Rajesh R Singh2, Russell R Broaddus1, Bedia A Barkoh2, Jawad Manekia2, Hui Yao3, L Jeffrey Medeiros2, Gregg Staerkel1, Rajyalakshmi Luthra2, John Stewart1.   

Abstract

BACKGROUND: The use of cytology specimens for next-generation sequencing (NGS) is particularly challenging because of the unconventional substrate of smears and the often limited sample volume. An analysis of factors affecting NGS testing in cytologic samples may help to increase the frequency of successful testing.
METHODS: This study reviewed variables associated with all in-house cytology cases (n = 207) that were analyzed by NGS with the Ion Torrent platform during a 10-month interval. A statistical analysis was performed to measure the effects of the DNA input threshold, specimen preparation, slide type, tumor fraction, DNA yield, and cytopathologist bias.
RESULTS: One hundred sixty-four of 207 cases (79%) were successfully sequenced by NGS; 43 (21%) failed because of either a low DNA yield or a template/library preparation failure. The median estimated tumor fraction and DNA concentration for the successfully sequenced cases were 70% and 2.5 ng/μL, respectively, whereas they were 60% and 0.2 ng/μL, respectively, for NGS failures. Cell block sections were tested in 91 cases, and smears were used in 116 cases. NGS success positively correlated with the DNA yield but not the tumor fraction. Cell block preparations showed a higher success rate than smears. Frosted-tip slides yielded significantly more DNA than fully frosted slides. Lowering the input DNA concentration below the manufacturer's recommended threshold of 10 ng (>0.85 ng/μL) resulted in a marked increase in the NGS success rate from 58.6% to 89.8%.
CONCLUSIONS: The failure of NGS with cytology samples is usually a result of suboptimal DNA due to multiple pre-analytical factors. Knowledge of these factors will allow better selection of cytology material for mutational analysis.
© 2015 American Cancer Society.

Entities:  

Keywords:  Ion Torrent; cytology; limited samples; molecular; mutational analysis; next-generation sequencing; pre-analytical factors

Mesh:

Year:  2015        PMID: 26230354     DOI: 10.1002/cncy.21597

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  27 in total

1.  Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies.

Authors:  Sinchita Roy-Chowdhuri; Hui Chen; Rajesh R Singh; Savitri Krishnamurthy; Keyur P Patel; Mark J Routbort; Jawad Manekia; Bedia A Barkoh; Hui Yao; Sharjeel Sabir; Russell R Broaddus; L Jeffrey Medeiros; Gregg Staerkel; John Stewart; Rajyalakshmi Luthra
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.

Authors:  Simon R Turner; Darren Buonocore; Patrice Desmeules; Natasha Rekhtman; Snjezana Dogan; Oscar Lin; Maria E Arcila; David R Jones; James Huang
Journal:  Lung Cancer       Date:  2018-03-07       Impact factor: 5.705

Review 3.  Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.

Authors:  Xiaomin Niu; Jody C Chuang; Gerald J Berry; Heather A Wakelee
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

4.  Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.

Authors:  Elizabeth M Jacobi; Gene Landon; Russell R Broaddus; Sinchita Roy-Chowdhuri
Journal:  Arch Pathol Lab Med       Date:  2020-03-30       Impact factor: 5.534

5.  Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).

Authors:  Marius Ilié; Véronique Hofman; Christophe Bontoux; Simon Heeke; Virginie Lespinet-Fabre; Olivier Bordone; Sandra Lassalle; Salomé Lalvée; Virginie Tanga; Maryline Allegra; Myriam Salah; Doriane Bohly; Jonathan Benzaquen; Charles-Hugo Marquette; Elodie Long-Mira; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

6.  Next-generation sequencing analyses using biopsy forceps and cytology brush rinse fluids for lung cancer genotyping: Report of five cases.

Authors:  Yoshimasa Nakazato; Hiromi Machida; Yukimi Horii; Masato Onozaki; Kensuke Ohikata; Yuko Kaneko; Ryo Arai; Seiji Niho; Kazuyuki Ishida
Journal:  Diagn Cytopathol       Date:  2021-08-25       Impact factor: 1.390

7.  Liquid biopsy assay for pulmonary adenocarcinoma using supernatants from core-needle biopsy specimens.

Authors:  Fanlei Kong; Yuanming Li; Runqi Guo; Li Yang; Jing Di; Lei He; Zheng Wang; Dongge Liu; Xiaoguang Li
Journal:  Thorac Cancer       Date:  2022-05-16       Impact factor: 3.223

8.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

Review 9.  Cell-blocks and other ancillary studies (including molecular genetic tests and proteomics).

Authors:  Vinod B Shidham
Journal:  Cytojournal       Date:  2021-02-22       Impact factor: 2.091

10.  Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.

Authors:  Elizabeth M Jacobi; Gene Landon; Russell R Broaddus; Sinchita Roy-Chowdhuri
Journal:  Arch Pathol Lab Med       Date:  2021-01-01       Impact factor: 5.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.